Bipolar Depression Market

DelveInsight’s Bipolar Depression market report provides thorough comprehension of Bipolar Depression, historical and forecasted epidemiology, and Bipolar Depression market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).

Key Takeaways from the Bipolar Depression Market Report

• According to the National Institute of Mental Health (NIMH), a branch of the National Institutes of Health, the 12-month prevalence of bipolar disorder among US adults aged 18 and older was found to be 2.8% based on diagnostic interview data from the National Comorbidity Survey Replication (NCS-R). It also stated that an estimated 4.4% of adults in the United States have bipolar disorder at some point in their lives.

• As per DelveInsight estimates, the total Bipolar Depression diagnosed prevalent cases were 2,401,287 in the US in 2020, which is further expected to increase by 2030.

• As per the estimates, the highest Bipolar Depression prevalent cases were of severe cases followed by moderate and mild in the UK in 2020.

• The leading pharma companies developing therapies to improve the Bipolar Depression treatment landscape include Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, and others.

• Key Bipolar Depression therapies in the pipeline include Caplyta (Lumateperone; ITI-007), NRX-100/NRX-101, Rexulti/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others.

• NeuroRx has developed a sequential therapy that consists of intravenous NRX-100 (ketamine HCL) for rapid stabilisation of depression and suicidal ideation, followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilisation from depression and suicidal ideation symptoms.

• SEP-4199 (Sunovion) is a non-racemic ratio of amisulpride enantiomers that has the potential to be the first benzamide treatment for mood disorders available in the United States.

• The Bipolar Depression market size is anticipated to grow at a CAGR of 11.9% during the study period (2017-30).

Want to learn more? Request for sample @ Bipolar Depression Market Outlook

Bipolar Depression: Overview

Bipolar Disorder (BD) is a mental illness marked by mood swings between depression and mania. BD is classified into four types based on the characteristics of the episodes: BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS).

Bipolar Depression Epidemiology Segmentation

The Bipolar Depression report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Bipolar Depression Total Diagnosed Prevalent Cases 

• Bipolar Depression Type-Specific Diagnosed Prevalent Cases 

• Bipolar Depression Severity-Specific Diagnosed Prevalent Cases

• Bipolar Depression Total Treated Cases

Bipolar Depression Treatment Landscape

Bipolar Depression treatment’s ultimate goal is to achieve a high level of psychosocial function and health-related quality of life. For bipolar depression patients, several off-label uses of therapies, or combinatorial therapy, are common. Anticonvulsants (such as Divalproex and Lamotrigine), Olanzapine monotherapy, and combined lithium and lamotrigine therapy have all been shown to reduce the severity of depressive symptoms in BD patients. Except for fluoxetine when combined with olanzapine, no antidepressant is explicitly approved by the FDA for bipolar depression treatment. 

Antidepressant monotherapy is discouraged in bipolar I disorder, mainly when mixed features are present and even when combined with a mood stabiliser. ECT, repetitive transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, lifestyle interventions, and psychotherapies are examples of non-pharmacological treatments for bipolar depression.

Apart from these, some FDA-approved drugs such as Olanzapine‐fluoxetine combination (OFC), Quetiapine, Lurasidone, and Cariprazine are also used for Bipolar Depression treatment. 

Bipolar Depression Market Outlook

The Bipolar Depression market size is anticipated to grow at a CAGR of 11.9% during the study period (2017-30). Furthermore, the Bipolar Depression treatment space will see a significant impact in the coming years as treatment improves over time along with the launch of novel therapies such as Caplyta, NRX-100/NRX-101, SEP-4199, and others.

For more information on the market outlook of bipolar depression, visit Bipolar Depression Market Size

Bipolar Depression Pipeline Therapies and Key Companies 

• Caplyta (Lumateperone; ITI-007): Intra-Cellular Therapies

• NRX-100/NRX-101: NeuroRx

• Rexulti/Rxulti (Brexpiprazole): Otsuka/ Lundbeck

• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)

• COMP 360 (Psilocybin Therapy): COMPASS Pathways

• Falkieri (Esketamine DPI): Celon Pharma

Bipolar Depression Market Drivers

• Future Directions in Blood Biomarkers

• Increase in Awareness and Technology

• Advances Toward Precision Medicine for BD

Bipolar Depression Market Barriers

• Misdiagnosis of Bipolar Depression

• Unsatisfactory Design of RCTs

• Limited Understanding of the Disease Mechanism

Scope of the Report

Bipolar Depression Key Companies: Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, among others. 

Bipolar Depression Key Pipeline Therapies: Caplyta (Lumateperone; ITI-007), NRX-100/NRX-101, Rexulti/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others.

Bipolar Depression Segmentation: By Geography, By Bipolar Depression therapies

Analysis: Comparative and conjoint analysis of Bipolar Depression emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Major Depressive Disorder Market 

Get a comprehensive analysis of Familial Hypercholesterolemia pipeline therapies and key companies such as Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, SAGE Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/